New	New	JJ	B-NP	O		0	3
one-week	one-week	JJ	I-NP	O		4	12
,	,	,	I-NP	O		12	13
low-dose	low-dose	JJ	I-NP	O		14	22
triple	triple	JJ	I-NP	O		23	29
therapy	therapy	NN	I-NP	O		30	37
for	for	IN	B-PP	O		38	41
the	the	DT	B-NP	O		42	45
treatment	treatment	NN	I-NP	O		46	55
of	of	IN	B-PP	O		56	58
duodenal	duodenal	JJ	B-NP	O		59	67
ulcer	ulcer	NN	I-NP	O		68	73
with	with	IN	B-PP	O		74	78
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O		79	98
infection	infection	NN	I-NP	O		99	108
.	.	.	O	O		108	109

Antimicrobial	Antimicrobial	JJ	B-NP	O		110	123
therapy	therapy	NN	I-NP	O		124	131
is	be	VBZ	B-VP	O		132	134
the	the	DT	B-NP	O		135	138
recommended	recommend	VBN	I-NP	O		139	150
treatment	treatment	NN	I-NP	O		151	160
for	for	IN	B-PP	O		161	164
duodenal	duodenal	JJ	B-NP	O		165	173
ulcer	ulcer	NN	I-NP	O		174	179
associated	associate	VBN	B-VP	O		180	190
with	with	IN	B-PP	O		191	195
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O		196	215
infection	infection	NN	I-NP	O		216	225
.	.	.	O	O		225	226

The	The	DT	B-NP	O		227	230
eradication	eradication	NN	I-NP	O		231	242
of	of	IN	B-PP	O		243	245
bismuth	bismuth	NN	B-NP	O		246	253
-	-	HYPH	O	O		253	254
based	base	VBN	B-NP	O		254	259
triple	triple	JJ	I-NP	O		260	266
therapy	therapy	NN	I-NP	O		267	274
with	with	IN	B-PP	O		275	279
bismuth	bismuth	JJ	B-NP	O		280	287
subcitrate	subcitrate	NN	I-NP	O		288	298
,	,	,	I-NP	O		298	299
metronidazole	metronidazole	NN	I-NP	O		300	313
and	and	CC	I-NP	O		314	317
amoxicillin	amoxicillin	NN	I-NP	O		318	329
is	be	VBZ	B-VP	O		330	332
limited	limit	VBN	I-VP	O		333	340
by	by	IN	B-PP	O		341	343
low	low	JJ	B-NP	O		344	347
compliance	compliance	NN	I-NP	O		348	358
,	,	,	O	O		358	359
drug	drug	NN	B-NP	O		360	364
resistance	resistance	NN	I-NP	O		365	375
and	and	CC	I-NP	O		376	379
side	side	NN	I-NP	O		380	384
-	-	HYPH	B-NP	O		384	385
effects	effect	NNS	I-NP	O		385	392
.	.	.	O	O		392	393

Two-week	Two-week	JJ	B-NP	O		394	402
proton	proton	NN	I-NP	O		403	409
pump	pump	NN	I-NP	O		410	414
inhibitor	inhibitor	NN	I-NP	O		415	424
(	(	(	O	O		425	426
PPI	PPI	NN	B-NP	O		426	429
)	)	)	O	O		429	430
-	-	HYPH	O	O		430	431
based	base	VBN	B-NP	O		431	436
triple	triple	JJ	I-NP	O		437	443
therapy	therapy	NN	I-NP	O		444	451
has	have	VBZ	B-VP	O		452	455
a	a	DT	B-NP	O		456	457
higher	high	JJR	I-NP	O		458	464
eradication	eradication	NN	I-NP	O		465	476
rate	rate	NN	I-NP	O		477	481
but	but	CC	O	O		482	485
is	be	VBZ	B-VP	O		486	488
costly	costly	JJ	B-ADJP	O		489	495
.	.	.	O	O		495	496

This	This	DT	B-NP	O		497	501
study	study	NN	I-NP	O		502	507
was	be	VBD	B-VP	O		508	511
designed	design	VBN	I-VP	O		512	520
to	to	TO	B-VP	O		521	523
compare	compare	VB	I-VP	O		524	531
the	the	DT	B-NP	O		532	535
efficacy	efficacy	NN	I-NP	O		536	544
,	,	,	O	O		544	545
patient	patient	NN	B-NP	O		546	553
compliance	compliance	NN	I-NP	O		554	564
and	and	CC	I-NP	O		565	568
cost	cost	NN	I-NP	O		569	573
of	of	IN	B-PP	O		574	576
short	short	JJ	B-NP	O		577	582
-	-	HYPH	I-NP	O		582	583
term	term	NN	I-NP	O		583	587
PPI	PPI	NN	I-NP	O		588	591
-	-	HYPH	B-VP	O		591	592
based	base	VBN	B-NP	O		592	597
triple	triple	JJ	I-NP	O		598	604
therapy	therapy	NN	I-NP	O		605	612
with	with	IN	B-PP	O		613	617
those	those	DT	B-NP	O		618	623
of	of	IN	B-PP	O		624	626
bismuth	bismuth	NN	B-NP	O		627	634
-	-	HYPH	O	O		634	635
based	base	VBN	B-NP	O		635	640
triple	triple	JJ	I-NP	O		641	647
therapy	therapy	NN	I-NP	O		648	655
.	.	.	O	O		655	656

Ninety	Ninety	CD	B-NP	O		657	663
patients	patient	NNS	I-NP	O		664	672
with	with	IN	B-PP	O		673	677
active	active	JJ	B-NP	O		678	684
duodenal	duodenal	JJ	I-NP	O		685	693
ulcer	ulcer	NN	I-NP	O		694	699
disease	disease	NN	I-NP	O		700	707
and	and	CC	O	O		708	711
H pylori	H_pylori	NN	B-NP	O		712	720
infection	infection	NN	I-NP	O		721	730
,	,	,	O	O		730	731
proven	prove	VBN	B-VP	O		732	738
with	with	IN	B-PP	O		739	743
the	the	DT	B-NP	O		744	747
13C	13C	NN	I-NP	O		748	751
-	-	HYPH	B-NP	O		751	752
urea	urea	NN	I-NP	O		752	756
breath	breath	NN	I-NP	O		757	763
test	test	NN	I-NP	O		764	768
and	and	CC	O	O		769	772
CLO	CLO	NN	B-NP	O		773	776
test	test	NN	I-NP	O		777	781
(	(	(	O	O		782	783
Campylobacter	Campylobacter	NN	B-NP	O		783	796
-	-	HYPH	B-NP	O		796	797
like	like	JJ	I-NP	O		797	801
organism	organism	NN	I-NP	O		802	810
test	test	NN	I-NP	O		811	815
)	)	)	O	O		815	816
were	be	VBD	B-VP	O		817	821
treated	treat	VBN	I-VP	O		822	829
randomly	randomly	RB	B-ADVP	O		830	838
in	in	IN	B-PP	O		839	841
three	three	CD	B-NP	O		842	847
therapeutic	therapeutic	JJ	I-NP	O		848	859
groups	group	NNS	I-NP	O		860	866
:	:	:	O	O		866	867
Group	Group	NN	B-NP	O		868	873
A	A	NN	I-NP	O		874	875
,	,	,	O	O		875	876
DeNol	DeNol	NN	B-NP	O		877	882
120	120	CD	I-NP	O		883	886
mg	mg	NN	I-NP	O		887	889
,	,	,	O	O		889	890
amoxicillin	amoxicillin	NN	B-NP	O		891	902
500	500	CD	I-NP	O		903	906
mg	mg	NN	I-NP	O		907	909
and	and	CC	I-NP	O		910	913
metronidazole	metronidazole	NN	I-NP	O		914	927
250	250	CD	I-NP	O		928	931
mg	mg	NN	I-NP	O		932	934
four	four	CD	B-NP	O		935	939
times	time	NNS	I-NP	O		940	945
a	a	DT	B-NP	O		946	947
day	day	NN	I-NP	O		948	951
orally	orally	RB	B-ADVP	O		952	958
for	for	IN	B-PP	O		959	962
14	14	CD	B-NP	O		963	965
days	day	NNS	I-NP	O		966	970
;	;	:	O	O		970	971
Group	Group	NN	B-NP	O		972	977
B	B	NN	I-NP	O		978	979
,	,	,	O	O		979	980
omeprazole	omeprazole	NN	B-NP	O		981	991
20	20	CD	I-NP	O		992	994
mg	mg	NN	I-NP	O		995	997
plus	plus	CC	O	O		998	1002
clarithromycin	clarithromycin	NN	B-NP	O		1003	1017
500	500	CD	I-NP	O		1018	1021
mg	mg	NN	I-NP	O		1022	1024
twice	twice	RB	B-NP	O		1025	1030
a	a	DT	I-NP	O		1031	1032
day	day	NN	I-NP	O		1033	1036
and	and	CC	O	O		1037	1040
amoxicillin	amoxicillin	NN	B-NP	O		1041	1052
500	500	CD	B-NP	O		1053	1056
mg	mg	NN	I-NP	O		1057	1059
four	four	CD	B-NP	O		1060	1064
times	time	NNS	I-NP	O		1065	1070
a	a	DT	B-NP	O		1071	1072
day	day	NN	I-NP	O		1073	1076
for	for	IN	B-PP	O		1077	1080
14	14	CD	B-NP	O		1081	1083
days	day	NNS	I-NP	O		1084	1088
;	;	:	O	O		1088	1089
Group	Group	NN	B-NP	O		1090	1095
C	C	NN	I-NP	O		1096	1097
,	,	,	O	O		1097	1098
omeprazole	omeprazole	NN	B-NP	O		1099	1109
20	20	CD	I-NP	O		1110	1112
mg	mg	NN	I-NP	O		1113	1115
,	,	,	O	O		1115	1116
clarithromycin	clarithromycin	NN	B-NP	O		1117	1131
250	250	CD	I-NP	O		1132	1135
mg	mg	NN	I-NP	O		1136	1138
and	and	CC	I-NP	O		1139	1142
metronidazole	metronidazole	NN	I-NP	O		1143	1156
500	500	CD	I-NP	O		1157	1160
mg	mg	NN	I-NP	O		1161	1163
twice	twice	RB	B-NP	O		1164	1169
a	a	DT	I-NP	O		1170	1171
day	day	NN	I-NP	O		1172	1175
for	for	IN	B-PP	O		1176	1179
seven	seven	CD	B-NP	O		1180	1185
days	day	NNS	I-NP	O		1186	1190
.	.	.	O	O		1190	1191

Nizatidine	Nizatidine	NN	B-NP	O		1192	1202
150	150	CD	I-NP	O		1203	1206
mg	mg	NN	I-NP	O		1207	1209
twice	twice	RB	B-NP	O		1210	1215
a	a	DT	I-NP	O		1216	1217
day	day	NN	I-NP	O		1218	1221
was	be	VBD	B-VP	O		1222	1225
given	give	VBN	I-VP	O		1226	1231
continuously	continuously	RB	B-ADVP	O		1232	1244
following	follow	VBG	B-PP	O		1245	1254
the	the	DT	B-NP	O		1255	1258
end	end	NN	I-NP	O		1259	1262
of	of	IN	B-PP	O		1263	1265
anti	anti	AFX	B-NP	O		1266	1270
-	-	HYPH	I-NP	O		1270	1271
H pylori	H_pylori	NN	I-NP	O		1271	1279
therapy	therapy	NN	I-NP	O		1280	1287
for	for	IN	B-PP	O		1288	1291
each	each	DT	B-NP	O		1292	1296
group	group	NN	I-NP	O		1297	1302
.	.	.	O	O		1302	1303

Two	Two	CD	B-NP	O		1304	1307
months	month	NNS	I-NP	O		1308	1314
later	later	RB	B-ADVP	O		1315	1320
,	,	,	O	O		1320	1321
endoscopy	endoscopy	NN	B-NP	O		1322	1331
,	,	,	O	O		1331	1332
the	the	DT	B-NP	O		1333	1336
CLO	CLO	NNP	I-NP	O		1337	1340
test	test	NN	I-NP	O		1341	1345
and	and	CC	I-NP	O		1346	1349
13C	13C	NN	I-NP	O		1350	1353
-	-	HYPH	B-NP	O		1353	1354
urea	urea	NN	I-NP	O		1354	1358
breath	breath	NN	I-NP	O		1359	1365
test	test	NN	I-NP	O		1366	1370
were	be	VBD	B-VP	O		1371	1375
repeated	repeat	VBN	I-VP	O		1376	1384
to	to	TO	B-VP	O		1385	1387
assess	assess	VB	I-VP	O		1388	1394
the	the	DT	B-NP	O		1395	1398
eradication	eradication	NN	I-NP	O		1399	1410
rate	rate	NN	I-NP	O		1411	1415
of	of	IN	B-PP	O		1416	1418
H pylori	H_pylori	NNP	B-NP	O		1419	1427
and	and	CC	O	O		1428	1431
the	the	DT	B-NP	O		1432	1435
ulcer	ulcer	NN	I-NP	O		1436	1441
-	-	HYPH	O	O		1441	1442
healing	heal	VBG	B-VP	O		1442	1449
rate	rate	NN	B-NP	O		1450	1454
.	.	.	O	O		1454	1455

Drug	Drug	NN	B-NP	O		1456	1460
tolerance	tolerance	NN	I-NP	O		1461	1470
was	be	VBD	B-VP	O		1471	1474
evaluated	evaluate	VBN	I-VP	O		1475	1484
by	by	IN	B-PP	O		1485	1487
patients	patient	NNS	B-NP	O		1488	1496
themselves	themselves	PRP	B-NP	O		1497	1507
by	by	IN	B-PP	O		1508	1510
daily	daily	JJ	B-NP	O		1511	1516
recording	recording	NN	I-NP	O		1517	1526
of	of	IN	B-PP	O		1527	1529
any	any	DT	B-NP	O		1530	1533
side	side	NN	I-NP	O		1534	1538
-	-	HYPH	B-NP	O		1538	1539
effects	effect	NNS	I-NP	O		1539	1546
.	.	.	O	O		1546	1547

Eighty	Eighty	CD	B-NP	O		1548	1554
-	-	HYPH	I-NP	O		1554	1555
four	four	CD	I-NP	O		1555	1559
patients	patient	NNS	I-NP	O		1560	1568
completed	complete	VBD	B-VP	O		1569	1578
the	the	DT	B-NP	O		1579	1582
entire	entire	JJ	I-NP	O		1583	1589
course	course	NN	I-NP	O		1590	1596
of	of	IN	B-PP	O		1597	1599
therapy	therapy	NN	B-NP	O		1600	1607
and	and	CC	I-NP	O		1608	1611
evaluation	evaluation	NN	I-NP	O		1612	1622
for	for	IN	B-PP	O		1623	1626
H pylori	H_pylori	NNP	B-NP	O		1627	1635
infection	infection	NN	I-NP	O		1636	1645
.	.	.	O	O		1645	1646

The	The	DT	B-NP	O		1647	1650
H pylori	H_pylori	NNP	I-NP	O		1651	1659
eradication	eradication	NN	I-NP	O		1660	1671
rates	rate	NNS	I-NP	O		1672	1677
in	in	IN	B-PP	O		1678	1680
Groups	Group	NNS	B-NP	O		1681	1687
A	A	NN	I-NP	O		1688	1689
,	,	,	O	O		1689	1690
B	B	NN	B-NP	O		1691	1692
and	and	CC	O	O		1693	1696
C	C	NN	B-NP	O		1697	1698
were	be	VBD	B-VP	O		1699	1703
75%	75%	CD	B-NP	O		1704	1707
(	(	(	O	O		1708	1709
21/28	21/28	CD	B-NP	O		1709	1714
)	)	)	O	O		1714	1715
,	,	,	O	O		1715	1716
93%	93%	CD	B-NP	O		1717	1720
(	(	(	O	O		1721	1722
26/28	26/28	CD	B-NP	O		1722	1727
)	)	)	O	O		1727	1728
and	and	CC	O	O		1729	1732
89%	89%	CD	B-NP	O		1733	1736
(	(	(	O	O		1737	1738
25/28	25/28	CD	B-NP	O		1738	1743
)	)	)	O	O		1743	1744
,	,	,	O	O		1744	1745
respectively	respectively	RB	B-ADVP	O		1746	1758
(	(	(	O	O		1759	1760
p	p	NN	B-NP	O		1760	1761
=	=	SYM	B-VP	O		1762	1763
0.466	0.466	CD	B-NP	O		1764	1769
)	)	)	O	O		1769	1770
.	.	.	O	O		1770	1771

The	The	DT	B-NP	O		1772	1775
ulcer	ulcer	NN	I-NP	O		1776	1781
healing	healing	NN	I-NP	O		1782	1789
rate	rate	NN	I-NP	O		1790	1794
was	be	VBD	B-VP	O		1795	1798
86%	86%	CD	B-NP	O		1799	1802
(	(	(	O	O		1803	1804
24/28	24/28	CD	B-NP	O		1804	1809
)	)	)	O	O		1809	1810
in	in	IN	B-PP	O		1811	1813
Group	Group	NN	B-NP	O		1814	1819
A	A	NN	I-NP	O		1820	1821
and	and	CC	O	O		1822	1825
89%	89%	NN	B-NP	O		1826	1829
(	(	(	O	O		1830	1831
25/28	25/28	CD	B-NP	O		1831	1836
)	)	)	O	O		1836	1837
in	in	IN	B-PP	O		1838	1840
Groups	Group	NNS	B-NP	O		1841	1847
B	B	NN	B-NP	O		1848	1849
and	and	CC	O	O		1850	1853
C	C	NN	B-NP	O		1854	1855
(	(	(	O	O		1856	1857
p	p	NN	B-NP	O		1857	1858
=	=	SYM	B-VP	O		1859	1860
0.764	0.764	CD	B-NP	O		1861	1866
)	)	)	O	O		1866	1867
.	.	.	O	O		1867	1868

A	A	DT	B-NP	O		1869	1870
total	total	NN	I-NP	O		1871	1876
of	of	IN	B-PP	O		1877	1879
74	74	CD	B-NP	O		1880	1882
patients	patient	NNS	I-NP	O		1883	1891
(	(	(	O	O		1892	1893
88%	88%	NN	B-NP	O		1893	1896
)	)	)	O	O		1896	1897
were	be	VBD	B-VP	O		1898	1902
free	free	JJ	B-ADJP	O		1903	1907
from	from	IN	B-PP	O		1908	1912
symptoms	symptom	NNS	B-NP	O		1913	1921
at	at	IN	B-PP	O		1922	1924
the	the	DT	B-NP	O		1925	1928
end	end	NN	I-NP	O		1929	1932
of	of	IN	B-PP	O		1933	1935
the	the	DT	B-NP	O		1936	1939
triple	triple	JJ	I-NP	O		1940	1946
therapy	therapy	NN	I-NP	O		1947	1954
.	.	.	O	O		1954	1955

Symptom	Symptom	NN	B-NP	O		1956	1963
relief	relief	NN	I-NP	O		1964	1970
was	be	VBD	B-VP	O		1971	1974
faster	fast	JJR	B-ADJP	O		1975	1981
in	in	IN	B-PP	O		1982	1984
patients	patient	NNS	B-NP	O		1985	1993
with	with	IN	B-PP	O		1994	1998
PPI	PPI	NN	B-NP	B-protein		1999	2002
-	-	HYPH	O	O		2002	2003
based	base	VBN	B-VP	O		2003	2008
triple	triple	JJ	B-NP	O		2009	2015
therapy	therapy	NN	I-NP	O		2016	2023
(	(	(	O	O		2024	2025
Groups	Group	NNS	B-NP	O		2025	2031
B	B	NN	B-NP	O		2032	2033
and	and	CC	O	O		2034	2037
C	C	NN	B-NP	O		2038	2039
)	)	)	O	O		2039	2040
(	(	(	O	O		2041	2042
days	day	NNS	B-NP	O		2042	2046
3	3	CD	B-NP	O		2047	2048
and	and	CC	I-NP	O		2049	2052
4	4	CD	I-NP	O		2053	2054
)	)	)	O	O		2054	2055
than	than	IN	B-PP	O		2056	2060
for	for	IN	B-PP	O		2061	2064
patients	patient	NNS	B-NP	O		2065	2073
with	with	IN	B-PP	O		2074	2078
bismuth	bismuth	NN	B-NP	O		2079	2086
-	-	HYPH	O	O		2086	2087
based	base	VBN	B-VP	O		2087	2092
triple	triple	JJ	B-NP	O		2093	2099
therapy	therapy	NN	I-NP	O		2100	2107
(	(	(	O	O		2108	2109
day	day	NN	B-NP	O		2109	2112
5	5	CD	I-NP	O		2113	2114
)	)	)	O	O		2114	2115
.	.	.	O	O		2115	2116

The	The	DT	B-NP	O		2117	2120
cost	cost	NN	I-NP	O		2121	2125
of	of	IN	B-PP	O		2126	2128
Group	Group	NN	B-NP	O		2129	2134
C	C	NN	I-NP	O		2135	2136
therapy	therapy	NN	I-NP	O		2137	2144
was	be	VBD	B-VP	O		2145	2148
lower	low	JJR	B-ADJP	O		2149	2154
than	than	IN	B-PP	O		2155	2159
that	that	DT	B-NP	O		2160	2164
for	for	IN	B-PP	O		2165	2168
Groups	Group	NNS	B-NP	O		2169	2175
A	A	NN	I-NP	O		2176	2177
and	and	CC	I-NP	O		2178	2181
B	B	NN	I-NP	O		2182	2183
.	.	.	O	O		2183	2184

There	There	EX	B-NP	O		2185	2190
were	be	VBD	B-VP	O		2191	2195
no	no	DT	B-NP	O		2196	2198
major	major	JJ	I-NP	O		2199	2204
side	side	NN	I-NP	O		2205	2209
-	-	HYPH	I-NP	O		2209	2210
effects	effect	NNS	I-NP	O		2210	2217
in	in	IN	B-PP	O		2218	2220
any	any	DT	B-NP	O		2221	2224
of	of	IN	B-PP	O		2225	2227
the	the	DT	B-NP	O		2228	2231
patients	patient	NNS	I-NP	O		2232	2240
.	.	.	O	O		2240	2241

One-week	One-week	JJ	B-NP	O		2242	2250
triple	triple	JJ	I-NP	O		2251	2257
therapy	therapy	NN	I-NP	O		2258	2265
with	with	IN	B-PP	O		2266	2270
omeprazole	omeprazole	NN	B-NP	O		2271	2281
,	,	,	I-NP	O		2281	2282
clarithromycin	clarithromycin	NN	I-NP	O		2283	2297
and	and	CC	I-NP	O		2298	2301
metronidazole	metronidazole	NN	I-NP	O		2302	2315
is	be	VBZ	B-VP	O		2316	2318
highly	highly	RB	I-VP	O		2319	2325
effected	effect	VBN	I-VP	O		2326	2334
for	for	IN	B-PP	O		2335	2338
the	the	DT	B-NP	O		2339	2342
eradication	eradication	NN	I-NP	O		2343	2354
of	of	IN	B-PP	O		2355	2357
H pylori	H_pylori	NNP	B-NP	O		2358	2366
.	.	.	O	O		2366	2367

A	A	DT	B-NP	O		2368	2369
therapeutic	therapeutic	JJ	I-NP	O		2370	2381
regime	regime	NN	I-NP	O		2382	2388
of	of	IN	B-PP	O		2389	2391
one	one	CD	B-NP	O		2392	2395
week's	week'	NNS	I-NP	O		2396	2402
duration	duration	NN	I-NP	O		2403	2411
with	with	IN	B-PP	O		2412	2416
lower	low	JJR	B-NP	O		2417	2422
cost	cost	NN	I-NP	O		2423	2427
,	,	,	O	O		2427	2428
good	good	JJ	B-NP	O		2429	2433
compliance	compliance	NN	I-NP	O		2434	2444
and	and	CC	O	O		2445	2448
mild	mild	JJ	B-NP	O		2449	2453
side	side	NN	I-NP	O		2454	2458
-	-	HYPH	B-NP	O		2458	2459
effects	effect	NNS	I-NP	O		2459	2466
may	may	MD	B-VP	O		2467	2470
offer	offer	VB	I-VP	O		2471	2476
a	a	DT	B-NP	O		2477	2478
good	good	JJ	I-NP	O		2479	2483
choice	choice	NN	I-NP	O		2484	2490
for	for	IN	B-PP	O		2491	2494
treatment	treatment	NN	B-NP	O		2495	2504
of	of	IN	B-PP	O		2505	2507
duodenal	duodenal	JJ	B-NP	O		2508	2516
ulcer	ulcer	NN	I-NP	O		2517	2522
associated	associate	VBN	B-VP	O		2523	2533
with	with	IN	B-PP	O		2534	2538
H pylori	H_pylori	NN	B-NP	O		2539	2547
infection	infection	NN	I-NP	O		2548	2557
in	in	IN	B-PP	O		2558	2560
clinical	clinical	JJ	B-NP	O		2561	2569
practice	practice	NN	I-NP	O		2570	2578
.	.	.	O	O		2578	2579

